This Article Full Text Full Text (PDF) Data Supplement Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Wen, S. Articles by Dichek, D. A. Search for Related Content PubMed PubMed Citation Articles by Wen, S. Articles by Dichek, D. A. Pubmed/NCBI databases Substance via MeSH Medline Plus Health Information Genes and Gene Therapy Related Collections Restenosis Growth factors/cytokines Gene therapy Other Vascular biology

(Arteriosclerosis, Thrombosis, and Vascular Biology. 2001;21:1777.)
© 2001 American Heart Association, Inc.

Vascular Biology

Inclusion of the E3 Region in an Adenoviral Vector Decreases Inflammation and Neointima Formation After Arterial Gene Transfer

Shan Wen; Robert M. Driscoll; Darren B. Schneider; David A. Dichek

From the Gladstone Institute of Cardiovascular Disease (S.W., R.M.D., D.B.S., D.A.D), Department of Medicine (D.A.D.), and Cardiovascular Research Institute (S.W., D.A.D.), University of California, San Francisco, and Department of Medicine, University of Washington (S.W., D.A.D.), Seattle.

Correspondence to Dr David A. Dichek, Division of Cardiology, Department of Medicine, University of Washington, 1959 NE Pacific St, Box 357710, Seattle, WA 98195-7710. E-mail ddichek{at}u.washington.edu

Abstract—— Adenoviral vectors are promising agents for vascular gene transfer. Their use, however, is limited by inflammatory host responses, neointima formation, and brevity of transgene expression. Inclusion of the immunomodulatory adenoviral E3 genes in a vector might prevent inflammation and neointima formation and prolong transgene expression. We compared 2 adenoviral vectors in a model of in vivo gene transfer to rabbit arteries. Both vectors expressed a luciferase reporter gene. One vector (AdE3Luc) contained the adenovirus early 3 (E3) region and the other (AdRSVLuc) lacked E3. Expression of E3 genes by AdE3Luc was confirmed in vitro and in vivo. Arteries transduced with AdE3Luc had substantially and significantly less inflammation (fewer T cells and lower levels of vascular cell adhesion molecule-1 and intercellular adhesion molecule 1 expression) and decreased neointima formation 14 days after gene transfer. Luciferase expression from the 2 vectors was equivalent, however, at both 3 and 14 days after gene transfer. Expression of E3 had no systemic immunosuppressive effects, as measured by peripheral blood counts and by assays for serum antibodies to adenovirus. We conclude that expression of E3 significantly decreases adenovirus-induced arterial wall inflammation and neointima formation. Because inflammation and neointima formation are major barriers to the clinical application of adenoviral vectors, use of E3-containing vectors improves the promise of adenovirus-mediated arterial gene transfer.

Key Words: adenovirus • carotid arteries • cell adhesion molecules • gene therapy • inflammation

This article has been cited by other articles:

				S. P. Fessler, Y. R. Chin, and M. S. Horwitz Inhibition of Tumor Necrosis Factor (TNF) Signal Transduction by the Adenovirus Group C RID Complex Involves Downregulation of Surface Levels of TNF Receptor 1 J. Virol., December 1, 2004; 78(23): 13113 - 13121. [Abstract] [Full Text] [PDF]

				S. Wen, S. Graf, P. G. Massey, and D. A. Dichek Improved Vascular Gene Transfer With a Helper-Dependent Adenoviral Vector Circulation, September 14, 2004; 110(11): 1484 - 1491. [Abstract] [Full Text] [PDF]

				J. Schaack, M. L. Bennett, J. D. Colbert, A. V. Torres, G. H. Clayton, D. Ornelles, and J. Moorhead E1A and E1B proteins inhibit inflammation induced by adenovirus PNAS, March 2, 2004; 101(9): 3124 - 3129. [Abstract] [Full Text] [PDF]